Announcements Trials
Browse Landscape

Phase

Phase 2/3 1

Status

Recruiting 1

Sponsor Class

OTHER 1

Study Type

Interventional 1

Sponsor

Cancer Type

Other hematologic neoplasm 1Lymphoid 1

Conditions

Precursor T-Cell Lymphoblastic Leukemia-Lymphoma 1Precursor Cell Lymphoblastic Leukemia-Lymphoma 1Leukemia, Myeloid, Acute 1

Interventions

Vincristine 3Cyclophosphamide 3calaspargase pegol 2Radiotherapy 2Prednisone 2Methotrexate 2Etoposide 2Doxorubicin 2Dexamethasone 2Daunorubicin 2Cytarabine 2Asparaginase 2venetoclax 1prednylidene 1pegaspargase 1nelarabine 1merphos 1fludarabine phosphate 1exifone 1dexamethasone acetate 1dexamethasone 21-phosphate 1deltacortene 1daratumumab 1auricularum 1Whole-Body Irradiation 1VAP-cyclo protocol 1Thiotepa 1Thioguanine 1Spinal Puncture 1Specimen Handling 1

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
Phase 2/3 × Precursor T-Cell Lymphoblastic Leukemia-Lymphoma × Homoharringtonine × Clear all
NCT06855810 2025-08-26

CCCG-TALL-2025

Institute of Hematology & Blood Diseases Hospital, China

Phase 2/3 Recruiting
610 enrolled
LymphoidOther hematologic neoplasm

Precursor Cell Lymphoblastic Leukemia-Lymphoma, Precursor T-Cell Lymphoblastic Leukemia-Lymphoma

Data powered by HemOnc (CC BY 4.0) Colophon âš¡